{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:00:50Z","timestamp":1782446450971,"version":"3.54.5"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01342","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:00:42Z","timestamp":1573221642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone\/Sulbactam"],"prefix":"10.3389","volume":"10","author":[{"given":"Ling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21307\/immunohematology-2019-098","article-title":"Drug-induced immune hemolytic anemia: the last 30 years of changes","volume":"30","author":"Arndt","year":"2014","journal-title":"Immunohematology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3343\/kjlm.2009.29.6.578","article-title":"A case of immune hemolytic anemia induced by ceftizoxime and cefobactam (sulbactam\/cefoperazone)","volume":"29","author":"Baek","year":"2009","journal-title":"Korean J. Lab. Med."},{"key":"B3","first-page":"265","article-title":"Chinese consensus on the diagnosis and treatment of autoimmune hemolytic anemia","volume":"38","year":"2017","journal-title":"Chin. J. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00228-016-2045-x","article-title":"Pharmacokinetics of cefoperazone\/sulbactam in critically ill patients receiving continuous venovenous hemofiltration","volume":"72","author":"Gao","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2141.2011.08784.x","article-title":"Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study","volume":"154","author":"Garbe","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14740338.2012.678832","article-title":"Immune hemolytic anemia caused by drugs","volume":"11","author":"Garratty","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"B7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21307\/immunohematology-2019-100","article-title":"Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007","volume":"30","author":"Garratty","year":"2014","journal-title":"Immunohematology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5045\/kjh.2007.42.3.288","article-title":"A pediatric case of autoimmune hemolytic anemia followed by excessive thrombocytosis and leukocytosis","volume":"42","author":"Jea","year":"2007","journal-title":"Korean J. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s00535-012-0579-y","article-title":"Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C","volume":"47","author":"Kobayashi","year":"2012","journal-title":"J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0887-7963(93)70142-X","article-title":"Mechanisms of drug-induced immunologically mediated cytopenias","volume":"7","author":"Shulman","year":"1993","journal-title":"Transfus. Med. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/jac\/dky323","article-title":"Comparison of empirical therapy with cefoperazone\/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae","volume":"73","author":"Su","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","article-title":"Approach to the patient with thrombocytosis. UP to date","author":"Tefferi","year":"2018"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T03:23:23Z","timestamp":1664853803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":14,"alternative-id":["10.3389\/fphar.2019.01342"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01342","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"article-number":"1342"}}